Can-fite Biopharma Ltd. · TASE:CANF
Can-fite Biopharma — Investor Presentation (July 2014)
20 slides from Can-fite Biopharma's investor presentation, Jul 8, 2014
Slide 1: Can-Fite Presentation — July 2014
BioPharma Ltd. ‘. CANFITE Can-Fite Presentation — July 2014 ‘Small Molecules For Big Clinical Needs™ (NYSE MKT:CANF) (TASE:CFBI)
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation contains forward-looking statements, about Can-Fite’s expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies or prospects. In addition, from time
Slide 3: Why Cancer Does Not Metastasize to Muscle
F Concept to Technolog Why Cancer ss Does Not Metastasize to Muscle Muscle? Smait & > Motecuies| | aa Cancer 0 Inflammatory all | Apoptosis = — , (Celt Death) {_ tam A, Adenosine Receptor wy | (NYSE MKT:CANF) (TASE:CFBI)
Slide 4: Platform Technology
Platform Technolog * Therapeutic Target ~ * As adenosine receptor (A3AR) * Highly expressed in inflammatory cells Inflammatory / Tumor Cells . Drug product * Small molecules * Orally bioavailable drugs * AGAR ligands . Pharmacology profile Reeecae * Anti-inflammatory and anti-cancer effects Therapeu
Slide 5: Company Profile
Company Profile * Can-Fite BioPharma Advanced clinical stage drug development company * Platform technology Small molecule ligands targeting the A3 adenosine receptor to treat: * Autoimmune Inflammatory diseases * Cancer * Ophthalmic diseases * Two regional out-licensing deals * Japan: for inflammat
Slide 6: Equity Profile
Equity Profile Ticker on NYSE: CANF Ticker on Israeli TASE: CFBI Price of ADR: $3.75 (1 ADR = 2 Ordinary Shares) 52 Week Range: $3.30 - $9.46 Shares Out: 17.7M Ordinary Shares Market Capitalization: ~S33M Avg. Trading Volume (30 day): 25,437 ADRs As of July 6, 2014 ____ (NYSE MKT:CANF) (TASE:CFB!) C
Slide 7: Market Opportunity
Market Opportunity Psoriasis Rheumatoid Arthritis 38.50$ Billions 2010 2018 2010 2017 Liver Cancer Glaucoma ste neroase zon 2015 2010 2018 “Global Data, GIA, Visiongain (NYSE MKT:CANF) (TASE:CFB!) CANFITE 7 BioPharma Lid.
Slide 8: Drug Development Pipeline
ug Development Pipelin Indication/Drug Pre-clinical Phase! Phasell Phase lll Psoriasis - C101 I ND © rosie interim anys Rheumatoid Arthritis - CF101 I GY success conctucica Inflammation - CF602 TI) ongoing Liver Cancer - CF102 m | | @ Ongoing (NYSE MKT:CANF) (TASE:CFB!) CANFITE 8 BioPharma Lid.
Slide 9: Corporate Partnership
Corporate Partnership Regional out-licensing deals t] SEIKAGAKU CORPORATION. [Tr2ded on the Tolyo Stock Exchange (Ticker:#543)] * Exclusive license to develop and commercialize CF101 in Japan * Up to $20M in upfront, milestone and annual payments ($7.5M received to date) * Up to 12% royalties @EVANG
Slide 10: CF101 Drug Profile
F10 rug Profile Properties * Highly Selective AsAR Agonist * Nucleoside derivative * Molecular weight - 510.29 © Water insoluble * Orally bioavailable * Half life time in blood — 8-9 hours * Is not metabolized in the body (secreted unchanged) ¢ CO Fishmanet al. Drug Discovery Today 17:359-366. 2011.
Slide 11: CF101 — Phase II Rheumatoid Arthritis Study
CF101 — Phase II Rheumatoid ritis Study Study Rationale - Phase Ila Data Phase Ila Data * Strong correlation found between A3AR expression in PBMNCs g 2 {a class of circulating white blood cells) at baseline and response of patients to CF101 drug treatment 5 4 — | a2 5070 AACR Response Phase Il - St
Slide 12: RA Phase II — Efficacy
RA Phase II — Efficacy 70% of patients had an over-expression of the Biomarker (>1.5 units) . and were eligible to be enrolled to the study ACR Response Rates p=0.035 50% o 4 6 «2 Treatment week FA Pl me WCFI01 & Placebo 20% ACR Response Rates ACR20 (NYSE MKT:CANF) (TASE:CFBI) CANFITE . 2 BioPharma
Slide 13: RA Phase II — Efficacy in Naive Patients
F Phase II — Efficacy in Naive Patients Patients with No Prior Systemic Therapy ACR Response Rates - Naive Patients @ CF101 (n=8) rs 1B Placebo (n=8) 50% 30% 20% > = ACR20 ACR50 ACR70 ACR Response Rates r 2 (NYSE MKT:CANF) (TASE:CFB!) CANFITE B BioPharma Lid.
Slide 14: CF101 - Psoriasis
CF101 - Psoriasis Phase II/Ill - Study Protocol Before After * Double-blind, placebo-controlled study to test efficacy of CF101 in 300 patients with moderate-to-severe plaque psoriasis * 3 arms: 1 mg, 2 mg and of CF101 and placebo * Allpatients receiving placebo were switched to either 1. mg or 2 mg
Slide 15: Psoriasis - Interim Analysis Data
Psoriasis - Interim Analysis Data Percent of PGA Response PGA 60) + cFIOV1mg 2mgvs1mg —e cFIOI 2mg P=0.0153 —O- Placebo =>» Placebo/t mg +O Placebol2 mg Treatment week Percent of PGA Response PASI 75 —e CFIO 1 mg —e CFI012mg —O- Placebo =» Placebo! mg +O Placebol2 mg 0 4 8 2 6 2m 2 Treatment week (N
Slide 16: CF102 for the Treatment of Liver Cancer
F102 for the Treatment of Liver Cancer Properties * Highly Selective A3AR Agonist * Nucleoside derivative * Molecular weight - 544.73 © Water insoluble * Orally bioavailable * Half life time in blood — 12 hours Anti-Cancer Effect Proof of concept in pre-clinical pharmacology studies: * Hepatocellula
Slide 17: CF102 for the Treatment of Liver Cancer
F CF102 e Treatment of Liver Cance Phase I/II Proof of Concept Study Study Synopsis Phase I/II, open-label, dose-escalation study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of orally administered CF102 in patients with advanced primary liver cancer Results * Very fav
Slide 18: Intellectual Property Portfolio
Intellectual Property Portfolio v Exclusive licensee of the U.S. National Institutes of Health (NIH) and Leiden University in the Netherlands for patents covering AsAR Agonists v 15 patent families v 150 patents issued and pending patents applications internationally Y IP covers composition of matte
Slide 19: Upcoming Milestones
potlig Indication Liver Cancer Rheumatoid Arthritis Psoriasis Biomarker 4 Milestones Milestone Patients’ enrollment to Phase II 78 patients study Phase III planning Data from Phase II/III 300 patients study Development of a commercial kit Status Initiation: Q3-2014 Q4-2014 Q1-2015 2014 (NYSE MKT:CAN
Slide 20: Can-Fite Presentation — July 2014
‘ CANFITE BioPharma Ltd. —= Can-Fite Presentation — July 2014 ‘Small Molecules For Big Clinical Needs™ Py (NYSE MKT:CANF) (TASE:CFBI)
Can-Fite BioPharma — Investor Presentation (July 2014) on 6ix